CTOs on the Move

Delfi Diagnostics

www.delfidiagnostics.com

 
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Tobias Mann
Vice President of Software Engineering and Information Technology Profile
Timothy McDaniel
Vice President of Technology Development Profile

Funding

Delfi Diagnostics raised $100M on 01/12/2021

Similar Companies

Rgenta Therapeutics

Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs

Specialty Hospital Of Midwest City

Specialty Hospital Of Midwest City is a Oklahoma City, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GlobeImmune

GlobeImmune is a Louisville, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Capital Technology Information Services

Capital Technology Information Services is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Virtual Radiologic Corporation

Virtual Radiologic (vRad) is a technology-enabled national radiology practice working in partnership with local radiologists and hospitals to optimize radiology’s pivotal role in patient care. vRad’s more than 400 radiologists serve 2,000+ facilities, reading 7 million studies annually. Delivering access to extensive subspecialty coverage, vRad contributes to improved quality of patient care. And with its next-generation technology, vRad enhances productivity, helping to lower the overall cost of care while expediting time to accurate diagnosis and treatment.